David Williams
Concepts (535)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Enzyme Inhibitors | 6 | 2023 | 446 | 0.900 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2023 | 17 | 0.690 |
Why?
| Hypophosphatasia | 1 | 2018 | 8 | 0.680 |
Why?
| Genetic Engineering | 1 | 2018 | 27 | 0.670 |
Why?
| Alkaline Phosphatase | 1 | 2018 | 99 | 0.650 |
Why?
| Phenylenediamines | 1 | 2018 | 5 | 0.640 |
Why?
| Disease Models, Animal | 5 | 2019 | 1647 | 0.620 |
Why?
| Cerebrovascular Circulation | 3 | 2016 | 137 | 0.590 |
Why?
| Retroviridae Infections | 2 | 2013 | 2 | 0.570 |
Why?
| Proto-Oncogene Proteins c-met | 5 | 2010 | 21 | 0.570 |
Why?
| Personnel, Hospital | 2 | 2006 | 23 | 0.550 |
Why?
| Tinnitus | 2 | 2017 | 62 | 0.550 |
Why?
| Aminopyridines | 3 | 2010 | 16 | 0.540 |
Why?
| Transcranial Magnetic Stimulation | 2 | 2017 | 81 | 0.530 |
Why?
| Suction | 2 | 2013 | 22 | 0.500 |
Why?
| Amines | 2 | 2014 | 46 | 0.480 |
Why?
| Female | 49 | 2024 | 28471 | 0.470 |
Why?
| Macaca mulatta | 2 | 2013 | 106 | 0.470 |
Why?
| Methamphetamine | 5 | 2014 | 233 | 0.460 |
Why?
| Xenotropic murine leukemia virus-related virus | 1 | 2012 | 1 | 0.450 |
Why?
| Humans | 62 | 2024 | 54391 | 0.440 |
Why?
| Wounds and Injuries | 2 | 2006 | 321 | 0.420 |
Why?
| Rural Health Services | 2 | 2013 | 175 | 0.420 |
Why?
| Structure-Activity Relationship | 11 | 2023 | 423 | 0.410 |
Why?
| Protein Kinase Inhibitors | 3 | 2010 | 216 | 0.410 |
Why?
| Heart Rate | 5 | 2019 | 358 | 0.410 |
Why?
| Male | 44 | 2024 | 27347 | 0.410 |
Why?
| Antibodies, Monoclonal | 5 | 2014 | 564 | 0.400 |
Why?
| Caregivers | 3 | 2019 | 241 | 0.400 |
Why?
| Intermittent Positive-Pressure Ventilation | 1 | 2011 | 20 | 0.390 |
Why?
| Infant, Very Low Birth Weight | 1 | 2011 | 47 | 0.380 |
Why?
| Cost-Benefit Analysis | 2 | 2015 | 291 | 0.370 |
Why?
| United States Department of Veterans Affairs | 3 | 2021 | 305 | 0.370 |
Why?
| Obesity | 6 | 2024 | 1203 | 0.370 |
Why?
| Depressive Disorder | 2 | 2010 | 368 | 0.360 |
Why?
| Telemedicine | 3 | 2013 | 453 | 0.360 |
Why?
| Intubation, Intratracheal | 1 | 2011 | 129 | 0.350 |
Why?
| Antineoplastic Agents | 5 | 2010 | 1300 | 0.350 |
Why?
| Maternal Nutritional Physiological Phenomena | 2 | 2020 | 51 | 0.350 |
Why?
| Breast Feeding | 2 | 2022 | 191 | 0.350 |
Why?
| Animals | 30 | 2021 | 14409 | 0.350 |
Why?
| Respiration, Artificial | 2 | 2016 | 286 | 0.340 |
Why?
| Dietary Supplements | 3 | 2018 | 457 | 0.330 |
Why?
| Time Factors | 10 | 2020 | 3210 | 0.310 |
Why?
| Gait Disorders, Neurologic | 2 | 2018 | 36 | 0.310 |
Why?
| Insulin Resistance | 2 | 2020 | 300 | 0.300 |
Why?
| Blood Pressure | 4 | 2016 | 587 | 0.300 |
Why?
| Leptin | 2 | 2022 | 154 | 0.300 |
Why?
| Dietary Proteins | 2 | 2020 | 230 | 0.300 |
Why?
| Infant, Newborn | 9 | 2021 | 2923 | 0.290 |
Why?
| Brain | 5 | 2021 | 1392 | 0.280 |
Why?
| Accidents, Occupational | 1 | 2006 | 22 | 0.280 |
Why?
| Parkinson Disease | 2 | 2018 | 180 | 0.270 |
Why?
| Infant, Premature | 5 | 2016 | 337 | 0.260 |
Why?
| Adiposity | 2 | 2024 | 142 | 0.260 |
Why?
| Cerebral Hemorrhage | 2 | 2016 | 105 | 0.260 |
Why?
| Occupational Diseases | 1 | 2006 | 93 | 0.250 |
Why?
| Cross-Over Studies | 7 | 2017 | 250 | 0.240 |
Why?
| Rats, Sprague-Dawley | 13 | 2014 | 1664 | 0.240 |
Why?
| Pregnancy | 11 | 2024 | 2639 | 0.240 |
Why?
| Infant, Premature, Diseases | 2 | 2016 | 93 | 0.230 |
Why?
| Depression | 3 | 2014 | 596 | 0.230 |
Why?
| Ethers | 1 | 2023 | 6 | 0.230 |
Why?
| Veterans | 2 | 2021 | 619 | 0.230 |
Why?
| Insulin | 3 | 2022 | 511 | 0.230 |
Why?
| Executive Function | 2 | 2021 | 80 | 0.220 |
Why?
| Stress Disorders, Post-Traumatic | 2 | 2019 | 389 | 0.220 |
Why?
| Pyrroles | 3 | 2008 | 78 | 0.220 |
Why?
| Internship and Residency | 2 | 2019 | 501 | 0.220 |
Why?
| Sertraline | 2 | 2014 | 47 | 0.220 |
Why?
| Maternal-Fetal Exchange | 2 | 2020 | 45 | 0.210 |
Why?
| Adult | 17 | 2019 | 14207 | 0.210 |
Why?
| Students, Medical | 2 | 2017 | 178 | 0.210 |
Why?
| Liver Failure, Acute | 1 | 2022 | 64 | 0.200 |
Why?
| End Stage Liver Disease | 1 | 2022 | 44 | 0.200 |
Why?
| HeLa Cells | 2 | 2023 | 291 | 0.200 |
Why?
| Energy Metabolism | 2 | 2021 | 311 | 0.200 |
Why?
| Microsomes, Liver | 4 | 2018 | 214 | 0.200 |
Why?
| Phencyclidine | 2 | 2011 | 21 | 0.200 |
Why?
| Body Composition | 2 | 2020 | 349 | 0.200 |
Why?
| Olivary Nucleus | 2 | 2011 | 8 | 0.190 |
Why?
| Middle Aged | 12 | 2019 | 13082 | 0.190 |
Why?
| Myocardium | 2 | 2021 | 443 | 0.190 |
Why?
| Evoked Potentials | 1 | 2021 | 69 | 0.190 |
Why?
| Pedunculopontine Tegmental Nucleus | 2 | 2012 | 58 | 0.190 |
Why?
| Purkinje Cells | 2 | 2011 | 22 | 0.190 |
Why?
| Myoglobin | 1 | 2021 | 32 | 0.190 |
Why?
| Mice | 14 | 2021 | 6428 | 0.190 |
Why?
| Growth | 1 | 2020 | 43 | 0.190 |
Why?
| Infant Food | 1 | 2020 | 31 | 0.190 |
Why?
| Rats | 13 | 2014 | 3419 | 0.190 |
Why?
| Spumavirus | 1 | 2020 | 1 | 0.190 |
Why?
| Bottle Feeding | 1 | 2020 | 40 | 0.190 |
Why?
| Body Temperature Regulation | 1 | 2020 | 35 | 0.190 |
Why?
| Crystallography, X-Ray | 6 | 2010 | 178 | 0.180 |
Why?
| Brain Concussion | 1 | 2021 | 109 | 0.180 |
Why?
| Cocaine-Related Disorders | 2 | 2014 | 246 | 0.180 |
Why?
| Blood Glucose | 2 | 2020 | 489 | 0.180 |
Why?
| Concept Formation | 1 | 2019 | 11 | 0.180 |
Why?
| Acetaminophen | 2 | 2022 | 350 | 0.180 |
Why?
| Neurons | 3 | 2012 | 486 | 0.180 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 10 | 0.180 |
Why?
| Genome, Viral | 1 | 2020 | 100 | 0.180 |
Why?
| Temperature | 1 | 2020 | 177 | 0.180 |
Why?
| Eating | 1 | 2020 | 163 | 0.170 |
Why?
| Energy Intake | 1 | 2020 | 196 | 0.170 |
Why?
| Phenotype | 2 | 2021 | 819 | 0.170 |
Why?
| Diastole | 2 | 2016 | 79 | 0.170 |
Why?
| Patient Care Team | 3 | 2013 | 273 | 0.170 |
Why?
| Case-Control Studies | 4 | 2019 | 1229 | 0.170 |
Why?
| Middle Cerebral Artery | 2 | 2016 | 39 | 0.170 |
Why?
| Virus Replication | 1 | 2020 | 143 | 0.170 |
Why?
| Freezing Reaction, Cataleptic | 1 | 2018 | 8 | 0.170 |
Why?
| Diabetes, Gestational | 1 | 2019 | 54 | 0.170 |
Why?
| Cannabidiol | 1 | 2019 | 35 | 0.170 |
Why?
| Sheep | 1 | 2018 | 88 | 0.170 |
Why?
| Feedback | 1 | 2019 | 61 | 0.170 |
Why?
| Colorectal Surgery | 1 | 2018 | 18 | 0.170 |
Why?
| Pyridones | 2 | 2009 | 42 | 0.170 |
Why?
| Point Mutation | 1 | 2018 | 92 | 0.160 |
Why?
| Receptors, Growth Factor | 2 | 2008 | 6 | 0.160 |
Why?
| Athletic Injuries | 1 | 2021 | 226 | 0.160 |
Why?
| Burnout, Professional | 1 | 2019 | 57 | 0.160 |
Why?
| Certification | 1 | 2018 | 47 | 0.160 |
Why?
| Body Mass Index | 4 | 2024 | 712 | 0.160 |
Why?
| Bone Development | 1 | 2018 | 69 | 0.160 |
Why?
| Arkansas | 6 | 2019 | 2100 | 0.160 |
Why?
| Military Personnel | 2 | 2019 | 174 | 0.160 |
Why?
| Blood Flow Velocity | 3 | 2016 | 114 | 0.160 |
Why?
| Cell Line, Tumor | 7 | 2017 | 1551 | 0.160 |
Why?
| Mental Health Services | 1 | 2021 | 233 | 0.160 |
Why?
| Ethanol | 2 | 2011 | 323 | 0.160 |
Why?
| Child | 8 | 2024 | 7368 | 0.160 |
Why?
| Foot | 1 | 2018 | 50 | 0.160 |
Why?
| Treatment Outcome | 7 | 2017 | 5612 | 0.160 |
Why?
| Walking | 1 | 2018 | 110 | 0.150 |
Why?
| Action Potentials | 3 | 2012 | 131 | 0.150 |
Why?
| Cognition | 1 | 2020 | 350 | 0.150 |
Why?
| Proto-Oncogene Proteins | 2 | 2008 | 169 | 0.150 |
Why?
| Psychiatry | 2 | 2017 | 116 | 0.150 |
Why?
| United States | 7 | 2021 | 5208 | 0.150 |
Why?
| Parathyroid Hormone-Related Protein | 1 | 2017 | 24 | 0.150 |
Why?
| Cellular Microenvironment | 1 | 2017 | 27 | 0.150 |
Why?
| Platelet Activation | 1 | 2017 | 50 | 0.150 |
Why?
| Electroacupuncture | 1 | 2016 | 3 | 0.150 |
Why?
| Epinephrine | 1 | 2017 | 97 | 0.150 |
Why?
| Combat Disorders | 1 | 2016 | 42 | 0.140 |
Why?
| Blood Specimen Collection | 1 | 2016 | 39 | 0.140 |
Why?
| Risk Factors | 6 | 2019 | 3937 | 0.140 |
Why?
| Citrus paradisi | 2 | 2008 | 10 | 0.140 |
Why?
| Food-Drug Interactions | 2 | 2008 | 13 | 0.140 |
Why?
| Pilot Projects | 3 | 2017 | 807 | 0.140 |
Why?
| Neonatal Screening | 1 | 2016 | 50 | 0.140 |
Why?
| Quinolines | 2 | 2007 | 40 | 0.140 |
Why?
| Temporal Lobe | 2 | 2017 | 75 | 0.140 |
Why?
| Career Choice | 1 | 2017 | 114 | 0.140 |
Why?
| Attention | 1 | 2017 | 185 | 0.140 |
Why?
| Itraconazole | 2 | 2008 | 45 | 0.140 |
Why?
| Perception | 1 | 2017 | 142 | 0.140 |
Why?
| Serotonin | 1 | 2017 | 159 | 0.140 |
Why?
| Cerebral Ventricles | 1 | 2016 | 25 | 0.140 |
Why?
| Substance-Related Disorders | 2 | 2014 | 671 | 0.140 |
Why?
| Cell Membrane | 1 | 2017 | 279 | 0.140 |
Why?
| Pain | 2 | 2016 | 405 | 0.140 |
Why?
| Melatonin | 1 | 2015 | 15 | 0.140 |
Why?
| Antibodies, Viral | 2 | 2013 | 124 | 0.140 |
Why?
| Arterial Pressure | 1 | 2016 | 50 | 0.130 |
Why?
| Physicians | 1 | 2019 | 245 | 0.130 |
Why?
| Quality of Life | 2 | 2019 | 924 | 0.130 |
Why?
| Bone Neoplasms | 1 | 2017 | 193 | 0.130 |
Why?
| Muscle, Skeletal | 1 | 2021 | 847 | 0.130 |
Why?
| Cholinergic Agonists | 2 | 2011 | 17 | 0.130 |
Why?
| Blood Platelets | 1 | 2017 | 268 | 0.130 |
Why?
| Xenograft Model Antitumor Assays | 3 | 2010 | 219 | 0.130 |
Why?
| Quality-Adjusted Life Years | 2 | 2015 | 70 | 0.130 |
Why?
| Excitatory Amino Acid Agonists | 2 | 2011 | 23 | 0.120 |
Why?
| Amphetamine | 1 | 2014 | 42 | 0.120 |
Why?
| Signal Transduction | 2 | 2022 | 1752 | 0.120 |
Why?
| Cyclohexanecarboxylic Acids | 1 | 2014 | 21 | 0.120 |
Why?
| Massage | 1 | 2014 | 7 | 0.120 |
Why?
| Cell Differentiation | 1 | 2017 | 720 | 0.120 |
Why?
| Autistic Disorder | 1 | 2015 | 135 | 0.120 |
Why?
| Osteoclasts | 1 | 2017 | 469 | 0.120 |
Why?
| Equipment Failure Analysis | 1 | 2013 | 49 | 0.120 |
Why?
| Behavior Therapy | 1 | 2015 | 203 | 0.120 |
Why?
| Simian foamy virus | 1 | 2013 | 1 | 0.120 |
Why?
| Severity of Illness Index | 4 | 2022 | 1082 | 0.120 |
Why?
| Simian Acquired Immunodeficiency Syndrome | 1 | 2013 | 3 | 0.120 |
Why?
| gamma-Aminobutyric Acid | 1 | 2014 | 76 | 0.120 |
Why?
| Drinking | 2 | 2020 | 78 | 0.120 |
Why?
| Drug Contamination | 1 | 2012 | 4 | 0.110 |
Why?
| Kangaroo-Mother Care Method | 1 | 2013 | 6 | 0.110 |
Why?
| Aged | 6 | 2021 | 10060 | 0.110 |
Why?
| Biophysical Phenomena | 1 | 2012 | 20 | 0.110 |
Why?
| Bacillus | 1 | 2012 | 7 | 0.110 |
Why?
| Nebulizers and Vaporizers | 1 | 2013 | 56 | 0.110 |
Why?
| Double-Blind Method | 4 | 2017 | 743 | 0.110 |
Why?
| Antifungal Agents | 2 | 2008 | 363 | 0.110 |
Why?
| Albuterol | 1 | 2013 | 58 | 0.110 |
Why?
| Drug Overdose | 1 | 2014 | 154 | 0.110 |
Why?
| Binding Sites | 2 | 2014 | 440 | 0.110 |
Why?
| Saliva | 1 | 2013 | 63 | 0.110 |
Why?
| Registries | 1 | 2015 | 553 | 0.110 |
Why?
| Smoking | 1 | 2017 | 552 | 0.110 |
Why?
| Bronchodilator Agents | 1 | 2013 | 74 | 0.110 |
Why?
| Child, Preschool | 4 | 2024 | 4158 | 0.110 |
Why?
| Hydrocortisone | 1 | 2013 | 124 | 0.110 |
Why?
| Coculture Techniques | 1 | 2012 | 159 | 0.110 |
Why?
| Primary Health Care | 3 | 2013 | 398 | 0.110 |
Why?
| Cardiotonic Agents | 1 | 2013 | 95 | 0.110 |
Why?
| Hypotension | 1 | 2013 | 67 | 0.110 |
Why?
| Anthropometry | 2 | 2024 | 96 | 0.110 |
Why?
| DNA, Viral | 1 | 2012 | 143 | 0.110 |
Why?
| Dopamine | 1 | 2013 | 190 | 0.110 |
Why?
| Models, Biological | 3 | 2019 | 825 | 0.110 |
Why?
| Calcium Channels, N-Type | 1 | 2011 | 9 | 0.100 |
Why?
| Intralaminar Thalamic Nuclei | 1 | 2011 | 14 | 0.100 |
Why?
| Functional Laterality | 1 | 2012 | 99 | 0.100 |
Why?
| Fetal Death | 1 | 2011 | 22 | 0.100 |
Why?
| Sequence Analysis, DNA | 1 | 2012 | 274 | 0.100 |
Why?
| Pain Management | 1 | 2013 | 155 | 0.100 |
Why?
| Pons | 1 | 2011 | 19 | 0.100 |
Why?
| Stem Cell Transplantation | 1 | 2012 | 201 | 0.100 |
Why?
| Echoencephalography | 1 | 2011 | 9 | 0.100 |
Why?
| Patch-Clamp Techniques | 4 | 2012 | 148 | 0.100 |
Why?
| Brain Waves | 1 | 2011 | 23 | 0.100 |
Why?
| Dose-Response Relationship, Drug | 4 | 2019 | 1476 | 0.100 |
Why?
| Sleep, REM | 1 | 2011 | 51 | 0.100 |
Why?
| Polymerase Chain Reaction | 1 | 2012 | 531 | 0.100 |
Why?
| Blotting, Western | 1 | 2012 | 684 | 0.100 |
Why?
| Nerve Fibers | 1 | 2011 | 24 | 0.100 |
Why?
| Cells, Cultured | 2 | 2012 | 1737 | 0.100 |
Why?
| Neurogenesis | 1 | 2011 | 30 | 0.100 |
Why?
| Longitudinal Studies | 3 | 2021 | 742 | 0.100 |
Why?
| Stress, Psychological | 1 | 2013 | 270 | 0.090 |
Why?
| Electrocardiography | 1 | 2012 | 290 | 0.090 |
Why?
| Central Nervous System Depressants | 1 | 2011 | 78 | 0.090 |
Why?
| Farnesyltranstransferase | 2 | 2007 | 5 | 0.090 |
Why?
| Carbon Dioxide | 1 | 2011 | 103 | 0.090 |
Why?
| Social Environment | 1 | 2011 | 95 | 0.090 |
Why?
| Professional Role | 1 | 2011 | 88 | 0.090 |
Why?
| Administration, Oral | 4 | 2018 | 461 | 0.090 |
Why?
| Synapses | 1 | 2010 | 90 | 0.090 |
Why?
| Atrial Fibrillation | 1 | 2012 | 197 | 0.090 |
Why?
| Cerebellum | 1 | 2011 | 142 | 0.090 |
Why?
| Linear Models | 3 | 2016 | 308 | 0.090 |
Why?
| Parents | 1 | 2013 | 346 | 0.090 |
Why?
| Teaching | 1 | 2011 | 125 | 0.090 |
Why?
| Dihydropyridines | 1 | 2009 | 10 | 0.090 |
Why?
| Data Collection | 1 | 2011 | 320 | 0.090 |
Why?
| Cross-Sectional Studies | 3 | 2021 | 1696 | 0.090 |
Why?
| Chronic Disease | 1 | 2012 | 614 | 0.090 |
Why?
| Health Care Costs | 1 | 2010 | 175 | 0.090 |
Why?
| Drug Design | 1 | 2010 | 133 | 0.090 |
Why?
| Gestational Age | 3 | 2019 | 435 | 0.080 |
Why?
| Learning | 1 | 2011 | 171 | 0.080 |
Why?
| Diet, High-Fat | 2 | 2021 | 216 | 0.080 |
Why?
| Phosphotransferases | 1 | 2008 | 24 | 0.080 |
Why?
| Cooperative Behavior | 1 | 2010 | 253 | 0.080 |
Why?
| Young Adult | 5 | 2017 | 4318 | 0.080 |
Why?
| Body Weight | 2 | 2021 | 578 | 0.080 |
Why?
| Magnetic Resonance Imaging | 3 | 2021 | 1616 | 0.080 |
Why?
| Mice, Inbred Strains | 2 | 2019 | 199 | 0.080 |
Why?
| Stomach Neoplasms | 2 | 2008 | 174 | 0.080 |
Why?
| Urea | 1 | 2008 | 83 | 0.080 |
Why?
| Triazines | 1 | 2008 | 30 | 0.080 |
Why?
| Electroencephalography | 1 | 2010 | 357 | 0.080 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2008 | 52 | 0.080 |
Why?
| Liver | 3 | 2019 | 1226 | 0.080 |
Why?
| Beverages | 2 | 2008 | 83 | 0.080 |
Why?
| Logistic Models | 2 | 2012 | 991 | 0.080 |
Why?
| Plasmodium falciparum | 1 | 2007 | 18 | 0.080 |
Why?
| Breast Neoplasms | 1 | 2017 | 1249 | 0.080 |
Why?
| Adolescent | 5 | 2021 | 6900 | 0.080 |
Why?
| Antimalarials | 1 | 2007 | 30 | 0.080 |
Why?
| Swimming | 1 | 2006 | 30 | 0.070 |
Why?
| Running | 1 | 2006 | 23 | 0.070 |
Why?
| Glioma | 1 | 2007 | 79 | 0.070 |
Why?
| Bicycling | 1 | 2006 | 43 | 0.070 |
Why?
| Monitoring, Physiologic | 2 | 2019 | 136 | 0.070 |
Why?
| Chromatography, High Pressure Liquid | 2 | 2018 | 377 | 0.070 |
Why?
| Proportional Hazards Models | 1 | 2007 | 430 | 0.070 |
Why?
| Central Nervous System Stimulants | 1 | 2009 | 255 | 0.070 |
Why?
| Motor Activity | 3 | 2014 | 249 | 0.070 |
Why?
| Sulfonamides | 1 | 2007 | 146 | 0.070 |
Why?
| Receptors, Vasopressin | 1 | 2005 | 28 | 0.070 |
Why?
| Fetus | 3 | 2014 | 228 | 0.070 |
Why?
| Dogs | 2 | 2020 | 216 | 0.070 |
Why?
| Prospective Studies | 3 | 2019 | 2606 | 0.070 |
Why?
| Ambulatory Care | 2 | 2021 | 231 | 0.070 |
Why?
| Alkyl and Aryl Transferases | 1 | 2005 | 8 | 0.070 |
Why?
| Benzodiazepines | 1 | 2005 | 70 | 0.070 |
Why?
| Multiple Myeloma | 2 | 2012 | 3049 | 0.070 |
Why?
| Spheroids, Cellular | 1 | 2005 | 26 | 0.070 |
Why?
| Poliomyelitis | 1 | 2005 | 15 | 0.070 |
Why?
| Cell Survival | 3 | 2017 | 657 | 0.060 |
Why?
| Ambulatory Care Facilities | 2 | 2021 | 138 | 0.060 |
Why?
| Mice, Inbred C57BL | 2 | 2021 | 2001 | 0.060 |
Why?
| Area Under Curve | 3 | 2014 | 205 | 0.060 |
Why?
| Kinetics | 2 | 2020 | 692 | 0.060 |
Why?
| Cyclin-Dependent Kinases | 1 | 2004 | 35 | 0.060 |
Why?
| beta-Cyclodextrins | 1 | 2004 | 18 | 0.060 |
Why?
| Thiazoles | 1 | 2004 | 61 | 0.060 |
Why?
| Brain Neoplasms | 1 | 2007 | 285 | 0.060 |
Why?
| Predictive Value of Tests | 2 | 2017 | 1045 | 0.060 |
Why?
| Protein Binding | 3 | 2014 | 736 | 0.060 |
Why?
| Placebos | 2 | 2014 | 90 | 0.060 |
Why?
| Louisiana | 2 | 2019 | 58 | 0.060 |
Why?
| Insurance Benefits | 1 | 2003 | 8 | 0.060 |
Why?
| Insurance, Psychiatric | 1 | 2003 | 6 | 0.060 |
Why?
| Palmitates | 1 | 2022 | 28 | 0.050 |
Why?
| Cell Proliferation | 4 | 2008 | 1097 | 0.050 |
Why?
| Community Mental Health Services | 1 | 2003 | 59 | 0.050 |
Why?
| Health Services | 1 | 2003 | 80 | 0.050 |
Why?
| Odds Ratio | 2 | 2016 | 600 | 0.050 |
Why?
| L-Lactate Dehydrogenase | 1 | 2022 | 79 | 0.050 |
Why?
| Drug Evaluation, Preclinical | 2 | 2017 | 158 | 0.050 |
Why?
| Models, Molecular | 3 | 2009 | 423 | 0.050 |
Why?
| Sex Factors | 2 | 2019 | 766 | 0.050 |
Why?
| Clinical Competence | 2 | 2018 | 444 | 0.050 |
Why?
| Physical Therapy Modalities | 1 | 2021 | 41 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2019 | 1301 | 0.050 |
Why?
| Statistics, Nonparametric | 2 | 2012 | 232 | 0.050 |
Why?
| Medically Uninsured | 1 | 2021 | 51 | 0.050 |
Why?
| Glucose Tolerance Test | 1 | 2021 | 67 | 0.050 |
Why?
| Carbachol | 2 | 2011 | 33 | 0.050 |
Why?
| Psychiatric Status Rating Scales | 2 | 2013 | 346 | 0.050 |
Why?
| Sodium Channel Blockers | 2 | 2011 | 18 | 0.050 |
Why?
| Postural Balance | 1 | 2021 | 61 | 0.050 |
Why?
| Weight Gain | 1 | 2022 | 244 | 0.050 |
Why?
| Athletes | 1 | 2021 | 115 | 0.050 |
Why?
| Diet, Fat-Restricted | 1 | 2020 | 11 | 0.050 |
Why?
| Membrane Potentials | 2 | 2011 | 139 | 0.050 |
Why?
| Mice, Obese | 1 | 2020 | 22 | 0.050 |
Why?
| Veterans Health | 1 | 2021 | 73 | 0.050 |
Why?
| Body Fat Distribution | 1 | 2020 | 11 | 0.050 |
Why?
| Cytopathogenic Effect, Viral | 1 | 2020 | 5 | 0.050 |
Why?
| Attitude | 1 | 2021 | 81 | 0.050 |
Why?
| Macaca | 1 | 2020 | 7 | 0.050 |
Why?
| Analysis of Variance | 2 | 2013 | 634 | 0.050 |
Why?
| Animals, Newborn | 2 | 2012 | 396 | 0.050 |
Why?
| Reaction Time | 1 | 2021 | 227 | 0.050 |
Why?
| Fatty Acids | 1 | 2021 | 175 | 0.050 |
Why?
| Adipose Tissue, Brown | 1 | 2020 | 45 | 0.050 |
Why?
| Absorptiometry, Photon | 1 | 2020 | 174 | 0.050 |
Why?
| Neuroimaging | 1 | 2020 | 88 | 0.050 |
Why?
| Lipid Metabolism | 1 | 2021 | 194 | 0.050 |
Why?
| Alcoholism | 1 | 2003 | 249 | 0.040 |
Why?
| Oxidation-Reduction | 1 | 2021 | 383 | 0.040 |
Why?
| Memory | 1 | 2020 | 124 | 0.040 |
Why?
| Family Relations | 1 | 2019 | 25 | 0.040 |
Why?
| Patient Compliance | 2 | 2014 | 247 | 0.040 |
Why?
| Sex Characteristics | 1 | 2021 | 214 | 0.040 |
Why?
| Exercise | 1 | 2024 | 552 | 0.040 |
Why?
| Language | 1 | 2020 | 137 | 0.040 |
Why?
| Proteomics | 1 | 2022 | 343 | 0.040 |
Why?
| Phylogeny | 1 | 2020 | 269 | 0.040 |
Why?
| Cohort Studies | 2 | 2016 | 1546 | 0.040 |
Why?
| Students | 1 | 2021 | 209 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 171 | 0.040 |
Why?
| Mothers | 1 | 2021 | 248 | 0.040 |
Why?
| Specialty Boards | 1 | 2018 | 26 | 0.040 |
Why?
| Interpersonal Relations | 1 | 2019 | 115 | 0.040 |
Why?
| Neuropsychological Tests | 1 | 2020 | 363 | 0.040 |
Why?
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 206 | 0.040 |
Why?
| Mice, Knockout | 1 | 2021 | 927 | 0.040 |
Why?
| Retrospective Studies | 2 | 2012 | 6459 | 0.040 |
Why?
| Animals, Outbred Strains | 1 | 2017 | 13 | 0.040 |
Why?
| Caco-2 Cells | 2 | 2008 | 50 | 0.040 |
Why?
| Serotonin 5-HT2 Receptor Antagonists | 1 | 2017 | 9 | 0.040 |
Why?
| Transglutaminases | 1 | 2017 | 17 | 0.040 |
Why?
| Parietal Lobe | 1 | 2017 | 30 | 0.040 |
Why?
| Toxicity Tests | 1 | 2017 | 52 | 0.040 |
Why?
| Social Support | 1 | 2019 | 297 | 0.040 |
Why?
| Adaptation, Psychological | 1 | 2019 | 243 | 0.040 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 79 | 0.040 |
Why?
| Platelet Aggregation | 1 | 2017 | 82 | 0.040 |
Why?
| Polysaccharides | 1 | 2017 | 57 | 0.040 |
Why?
| Mice, Inbred BALB C | 2 | 2008 | 370 | 0.040 |
Why?
| Organ Size | 1 | 2017 | 237 | 0.040 |
Why?
| Accidental Falls | 1 | 2018 | 98 | 0.040 |
Why?
| Plant Extracts | 1 | 2019 | 193 | 0.040 |
Why?
| Cell Line | 1 | 2020 | 1152 | 0.040 |
Why?
| Medicine | 1 | 2017 | 58 | 0.040 |
Why?
| Prefrontal Cortex | 1 | 2017 | 89 | 0.040 |
Why?
| Emergency Service, Hospital | 1 | 2021 | 543 | 0.040 |
Why?
| Feeding Behavior | 1 | 2018 | 200 | 0.040 |
Why?
| Adrenergic beta-Antagonists | 1 | 2017 | 105 | 0.040 |
Why?
| Educational Measurement | 1 | 2018 | 232 | 0.040 |
Why?
| Protein Transport | 1 | 2017 | 195 | 0.040 |
Why?
| Mice, Nude | 2 | 2009 | 284 | 0.040 |
Why?
| Inhibitory Concentration 50 | 2 | 2008 | 80 | 0.040 |
Why?
| Education, Medical, Graduate | 1 | 2019 | 226 | 0.040 |
Why?
| Umbilical Arteries | 1 | 2016 | 22 | 0.040 |
Why?
| Prognosis | 1 | 2022 | 2126 | 0.040 |
Why?
| Pharmaceutical Solutions | 2 | 2008 | 8 | 0.040 |
Why?
| Cannabis | 1 | 2019 | 149 | 0.040 |
Why?
| Psychomotor Performance | 1 | 2017 | 156 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2017 | 252 | 0.040 |
Why?
| Ultrasonography, Doppler, Transcranial | 1 | 2016 | 26 | 0.030 |
Why?
| Apgar Score | 1 | 2016 | 35 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 319 | 0.030 |
Why?
| Autonomic Nervous System | 1 | 2016 | 75 | 0.030 |
Why?
| Tandem Mass Spectrometry | 1 | 2017 | 248 | 0.030 |
Why?
| Infant, Extremely Premature | 1 | 2016 | 31 | 0.030 |
Why?
| Echocardiography | 1 | 2018 | 392 | 0.030 |
Why?
| Prevalence | 1 | 2019 | 1025 | 0.030 |
Why?
| Platelet Aggregation Inhibitors | 1 | 2017 | 179 | 0.030 |
Why?
| Up-Regulation | 1 | 2017 | 509 | 0.030 |
Why?
| Cost of Illness | 1 | 2015 | 132 | 0.030 |
Why?
| Binding Sites, Antibody | 1 | 2014 | 26 | 0.030 |
Why?
| Calcium | 1 | 2017 | 434 | 0.030 |
Why?
| GABA Agonists | 1 | 2014 | 17 | 0.030 |
Why?
| Diagnosis, Dual (Psychiatry) | 1 | 2014 | 46 | 0.030 |
Why?
| Half-Life | 1 | 2014 | 92 | 0.030 |
Why?
| Locomotion | 1 | 2014 | 83 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2016 | 643 | 0.030 |
Why?
| CD4 Lymphocyte Count | 1 | 2013 | 35 | 0.030 |
Why?
| Particle Size | 1 | 2013 | 88 | 0.030 |
Why?
| T-Lymphocyte Subsets | 1 | 2013 | 41 | 0.030 |
Why?
| Administration, Inhalation | 1 | 2013 | 119 | 0.030 |
Why?
| MicroRNAs | 1 | 2017 | 386 | 0.030 |
Why?
| Aerosols | 1 | 2013 | 76 | 0.030 |
Why?
| Amphetamine-Related Disorders | 1 | 2014 | 125 | 0.030 |
Why?
| Biophysics | 1 | 2012 | 20 | 0.030 |
Why?
| Gene Expression Profiling | 1 | 2018 | 1141 | 0.030 |
Why?
| Infant, Extremely Low Birth Weight | 1 | 2013 | 30 | 0.030 |
Why?
| Nasal Cavity | 1 | 2013 | 16 | 0.030 |
Why?
| Viral Load | 1 | 2013 | 86 | 0.030 |
Why?
| Plasma | 1 | 2013 | 52 | 0.030 |
Why?
| Touch | 1 | 2013 | 27 | 0.030 |
Why?
| Theophylline | 1 | 2012 | 24 | 0.030 |
Why?
| Infant Behavior | 1 | 2013 | 18 | 0.030 |
Why?
| Medically Underserved Area | 1 | 2013 | 45 | 0.030 |
Why?
| Ion Channel Gating | 1 | 2012 | 47 | 0.030 |
Why?
| Neurotransmitter Agents | 1 | 2012 | 38 | 0.030 |
Why?
| Electric Stimulation | 1 | 2012 | 94 | 0.030 |
Why?
| Medication Adherence | 1 | 2014 | 133 | 0.030 |
Why?
| Remission Induction | 1 | 2013 | 222 | 0.030 |
Why?
| Intensive Care Units, Neonatal | 1 | 2014 | 117 | 0.030 |
Why?
| Drug Therapy, Combination | 1 | 2014 | 426 | 0.030 |
Why?
| Heart Atria | 1 | 2012 | 57 | 0.030 |
Why?
| Systole | 1 | 2012 | 80 | 0.030 |
Why?
| Equipment Design | 1 | 2013 | 318 | 0.030 |
Why?
| Ion Channels | 1 | 2012 | 75 | 0.030 |
Why?
| Sleep | 1 | 2014 | 188 | 0.030 |
Why?
| Psychotherapy | 1 | 2013 | 106 | 0.030 |
Why?
| Caffeine | 1 | 2012 | 77 | 0.030 |
Why?
| omega-Agatoxin IVA | 1 | 2011 | 4 | 0.030 |
Why?
| Recurrence | 1 | 2014 | 692 | 0.030 |
Why?
| Combined Modality Therapy | 1 | 2014 | 693 | 0.030 |
Why?
| Ventricular Dysfunction, Left | 1 | 2012 | 99 | 0.030 |
Why?
| Antidepressive Agents | 1 | 2013 | 187 | 0.030 |
Why?
| Infant | 1 | 2020 | 3829 | 0.030 |
Why?
| Oscillometry | 1 | 2011 | 9 | 0.030 |
Why?
| Sodium Channels | 1 | 2011 | 22 | 0.030 |
Why?
| Calcium Channel Blockers | 1 | 2011 | 72 | 0.030 |
Why?
| Secondary Prevention | 1 | 2011 | 89 | 0.020 |
Why?
| Survival Analysis | 1 | 2013 | 736 | 0.020 |
Why?
| Cystic Fibrosis | 1 | 2013 | 157 | 0.020 |
Why?
| Acculturation | 1 | 2011 | 23 | 0.020 |
Why?
| Social Identification | 1 | 2011 | 20 | 0.020 |
Why?
| Transplantation, Autologous | 1 | 2012 | 485 | 0.020 |
Why?
| Principal Component Analysis | 1 | 2011 | 71 | 0.020 |
Why?
| Fluorescent Antibody Technique | 1 | 2011 | 141 | 0.020 |
Why?
| Statistics as Topic | 1 | 2011 | 102 | 0.020 |
Why?
| Vesicular Glutamate Transport Protein 2 | 1 | 2010 | 8 | 0.020 |
Why?
| Clinical Clerkship | 1 | 2011 | 36 | 0.020 |
Why?
| Cerebellar Cortex | 1 | 2010 | 7 | 0.020 |
Why?
| Microscopy, Confocal | 1 | 2011 | 110 | 0.020 |
Why?
| Tetrodotoxin | 1 | 2010 | 11 | 0.020 |
Why?
| Muscarinic Agonists | 1 | 2010 | 12 | 0.020 |
Why?
| Electrophysiological Phenomena | 1 | 2010 | 20 | 0.020 |
Why?
| Theta Rhythm | 1 | 2010 | 12 | 0.020 |
Why?
| Potassium Channel Blockers | 1 | 2010 | 18 | 0.020 |
Why?
| N-Methylaspartate | 1 | 2010 | 27 | 0.020 |
Why?
| Femoral Artery | 1 | 2011 | 122 | 0.020 |
Why?
| Potassium Channels | 1 | 2010 | 41 | 0.020 |
Why?
| Kainic Acid | 1 | 2010 | 33 | 0.020 |
Why?
| Ultrasonography | 1 | 2012 | 486 | 0.020 |
Why?
| Schools, Medical | 1 | 2011 | 82 | 0.020 |
Why?
| Disease Progression | 1 | 2013 | 915 | 0.020 |
Why?
| Kaplan-Meier Estimate | 1 | 2011 | 514 | 0.020 |
Why?
| Cell Count | 1 | 2010 | 181 | 0.020 |
Why?
| Pregnancy Outcome | 1 | 2011 | 248 | 0.020 |
Why?
| Stereotyped Behavior | 1 | 2009 | 17 | 0.020 |
Why?
| Dextroamphetamine | 1 | 2009 | 36 | 0.020 |
Why?
| Kidney Diseases | 1 | 2012 | 293 | 0.020 |
Why?
| Image Processing, Computer-Assisted | 1 | 2011 | 256 | 0.020 |
Why?
| Solubility | 1 | 2009 | 75 | 0.020 |
Why?
| Incidence | 1 | 2012 | 1083 | 0.020 |
Why?
| Age Factors | 1 | 2013 | 1199 | 0.020 |
Why?
| Fetal Development | 1 | 2009 | 64 | 0.020 |
Why?
| Blood Proteins | 1 | 2009 | 100 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2009 | 231 | 0.020 |
Why?
| fms-Like Tyrosine Kinase 3 | 1 | 2008 | 16 | 0.020 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2008 | 37 | 0.020 |
Why?
| Ether-A-Go-Go Potassium Channels | 1 | 2008 | 5 | 0.020 |
Why?
| Parasitic Sensitivity Tests | 1 | 2007 | 2 | 0.020 |
Why?
| Dealkylation | 1 | 2007 | 5 | 0.020 |
Why?
| Plasmodium berghei | 1 | 2007 | 4 | 0.020 |
Why?
| Cell Membrane Permeability | 1 | 2007 | 28 | 0.020 |
Why?
| Mutagenicity Tests | 1 | 2007 | 56 | 0.020 |
Why?
| Risk Assessment | 1 | 2012 | 1362 | 0.020 |
Why?
| Cytochrome P-450 CYP3A | 1 | 2008 | 82 | 0.020 |
Why?
| Protein Conformation | 1 | 2008 | 226 | 0.020 |
Why?
| Kidney | 1 | 2012 | 822 | 0.020 |
Why?
| Hypertension | 1 | 2012 | 565 | 0.020 |
Why?
| Glutathione Transferase | 1 | 2008 | 178 | 0.020 |
Why?
| Malaria | 1 | 2007 | 37 | 0.020 |
Why?
| Bile Ducts | 1 | 2007 | 53 | 0.020 |
Why?
| Exercise Tolerance | 1 | 2006 | 48 | 0.020 |
Why?
| Physical Endurance | 1 | 2006 | 49 | 0.020 |
Why?
| Respiration | 1 | 2006 | 99 | 0.020 |
Why?
| Computer Simulation | 1 | 2007 | 332 | 0.020 |
Why?
| Hepatocytes | 1 | 2008 | 214 | 0.020 |
Why?
| Benzazepines | 1 | 2005 | 20 | 0.020 |
Why?
| Molecular Weight | 1 | 2005 | 100 | 0.020 |
Why?
| Oxygen Consumption | 1 | 2006 | 223 | 0.020 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 2006 | 255 | 0.020 |
Why?
| Drug Screening Assays, Antitumor | 1 | 2005 | 142 | 0.020 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2007 | 594 | 0.020 |
Why?
| Cyclodextrins | 1 | 2004 | 17 | 0.020 |
Why?
| Tumor Cells, Cultured | 1 | 2005 | 477 | 0.020 |
Why?
| Biological Availability | 1 | 2004 | 131 | 0.010 |
Why?
| Leukemia | 1 | 2004 | 69 | 0.010 |
Why?
| Neoplasms, Experimental | 1 | 2004 | 115 | 0.010 |
Why?
| Gatekeeping | 1 | 2003 | 12 | 0.010 |
Why?
| Cost Control | 1 | 2003 | 15 | 0.010 |
Why?
| Cost Sharing | 1 | 2003 | 18 | 0.010 |
Why?
| Tennessee | 1 | 2003 | 43 | 0.010 |
Why?
| Georgia | 1 | 2003 | 40 | 0.010 |
Why?
| Alabama | 1 | 2003 | 71 | 0.010 |
Why?
| Mississippi | 1 | 2003 | 103 | 0.010 |
Why?
| Health Policy | 1 | 2003 | 171 | 0.010 |
Why?
|
|
Williams's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|